Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Acer Therapeutics Inc.OPXA · Entity 108116 | Director | November 18, 2016 | November 22, 2016 |
| Cartesian Therapeutics, Inc.RNAC · Entity 6015 | Director | January 02, 2026 | January 06, 2026 |
| Heartflow, Inc.HTFL · Entity 3993 | Director | July 22, 2026 | July 24, 2026 |
| VEEVA SYSTEMS INCVEEV · Entity 2124 | Director | June 22, 2021 | June 23, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Acer Therapeutics Inc.
Report date November 18, 2016 · Filed November 22, 2016
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 12,910 |
Ending reported balance
After 2016-11-18 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2016-11-18 · Sale · Disposed 7,105 · Balance 20,719 Row 2 · 2016-11-18 · Sale · Disposed 7,809 · Balance 12,910 |
| Warrants (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.00 · Expires 2018-04-08 | Direct | 0 |
Reported balance
After 2016-11-18 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2016-11-18 · Sale · Disposed 16,000 · Balance 0 |
Cartesian Therapeutics, Inc.
Report date January 02, 2026 · Filed January 06, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 56,966 |
Reported balance
After 2026-01-02 transaction · row 1
1 source rowRow 1 · 2026-01-02 · Grant · Acquired 2,600 · Balance 56,966 F1: Each Restricted Stock Unit represents a contingent right to receive one share of common stock, which will vest in full on January 2, 2027. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.76 · Expires 2036-01-01 | Direct | 7,800 |
Reported balance
After 2026-01-02 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-01-02 · Grant · Acquired 7,800 · Balance 7,800 |
Filing footnotes · ownership attribution and instrument terms
F1: Each Restricted Stock Unit represents a contingent right to receive one share of common stock, which will vest in full on January 2, 2027.
Heartflow, Inc.
Report date July 22, 2026 · Filed July 24, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 188,231 |
Reported balance
After 2026-07-22 transaction · row 1
1 source rowRow 1 · 2026-07-22 · Exercise / conversion · Acquired 3,710 · Balance 188,231 |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $19.00 · Expires 2035-08-07 | Direct | 15,000 |
Reported balance
After 2026-07-22 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-07-22 · Exercise / conversion · Disposed 3,710 · Balance 15,000 F1: These stock options are fully exercisable. |
Filing footnotes · ownership attribution and instrument terms
F1: These stock options are fully exercisable.
VEEVA SYSTEMS INC
Report date June 22, 2021 · Filed June 23, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | Direct | 6,643 |
Reported balance
After 2021-06-22 transaction · row 1
1 source rowRow 1 · 2021-06-22 · Exercise / conversion · Acquired 251 · Balance 6,643 F1: Transaction exempt from Section 16(b) of the Securities Exchange Act of 1934 (the "Act") pursuant to Rule 16b-6(b) promulgated under the Act. F2: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Class A Common Stock of the Issuer. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2021-06-22 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2021-06-22 · Exercise / conversion · Disposed 251 · Balance 0 F2: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Class A Common Stock of the Issuer. F1: Transaction exempt from Section 16(b) of the Securities Exchange Act of 1934 (the "Act") pursuant to Rule 16b-6(b) promulgated under the Act. F3: On June 25, 2020, the Reporting Person was granted 1,003 RSUs under the Issuer's 2013 Equity Incentive Plan, of which 1/4 of the RSUs vested on September 25, 2020, with the remaining RSUs vesting equally on a quarterly basis thereafter, subject to continued service on the Issuer's board of directors on the applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Transaction exempt from Section 16(b) of the Securities Exchange Act of 1934 (the "Act") pursuant to Rule 16b-6(b) promulgated under the Act.
F2: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Class A Common Stock of the Issuer.
F3: On June 25, 2020, the Reporting Person was granted 1,003 RSUs under the Issuer's 2013 Equity Incentive Plan, of which 1/4 of the RSUs vested on September 25, 2020, with the remaining RSUs vesting equally on a quarterly basis thereafter, subject to continued service on the Issuer's board of directors on the applicable vesting date.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
ARQULE INC
Report date January 16, 2020 · Filed January 16, 2020
Section 16 reporting ended · disclosed 2020-01-16. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2020-01-16 transaction · row 1
1 source rowRow 1 · 2020-01-16 · Other · Disposed 146,897 · Balance 0 F1: On December 6, 2019, ArQule, Inc. (the "Company") entered into an Agreement and Plan of Merger (as amended, supplemented or otherwise modified from time to time, the "Merger Agreement") with Merck Sharpe & Dohme Corp. ("MSD") and Argon Merger Sub, Inc., a wholly-owned subsidiary of MSD ("Merger Sub"), pursuant to which MSD acquired the Company by a tender offer for all shares of Company common stock (the "Offer") and a subsequent merger (the "Merger"), each of which became effective on January 16, 2020. Pursuant to the Merger Agreement, (i) Merger Sub purchased all shares of Company common stock that were validly tendered pursuant to the Offer for a cash payment equal to $20.00 per share (the "Offer Price") and (ii) all shares of Company common stock outstanding immediately prior to the effective time of the Merger (the "Effective Time"), were cancelled and converted automatically into the right to receive the Offer Price. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.48 · Expires 2028-05-08 | Direct | 0 |
Reported balance
After 2020-01-16 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2020-01-16 · Disposition to issuer · Disposed 20,000 · Balance 0 F2: Pursuant to the Merger Agreement, immediately prior to the Effective Time, all outstanding Company stock options, to the extent unvested, became fully vested, and at the Effective Time, each outstanding Company stock option was cancelled and converted into the right to receive an amount of cash (subject to any applicable withholding or other taxes required by applicable law) determined by multiplying (i) the number of shares of Company common stock subject to such stock option immediately prior to such cancellation by (ii) the excess, if any, of an amount in cash equal to the Offer Price, without any interest, over the exercise price per share of Company common sotck subject to such stock option, less any applicable tax withholding. Any such option that had an exercise price that equaled or exceeded the Offer Price was cancelled for no consideration. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.21 · Expires 2029-05-13 | Direct | 0 |
Reported balance
After 2020-01-16 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2020-01-16 · Disposition to issuer · Disposed 40,000 · Balance 0 F2: Pursuant to the Merger Agreement, immediately prior to the Effective Time, all outstanding Company stock options, to the extent unvested, became fully vested, and at the Effective Time, each outstanding Company stock option was cancelled and converted into the right to receive an amount of cash (subject to any applicable withholding or other taxes required by applicable law) determined by multiplying (i) the number of shares of Company common stock subject to such stock option immediately prior to such cancellation by (ii) the excess, if any, of an amount in cash equal to the Offer Price, without any interest, over the exercise price per share of Company common sotck subject to such stock option, less any applicable tax withholding. Any such option that had an exercise price that equaled or exceeded the Offer Price was cancelled for no consideration. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.14 · Expires 2020-05-13 | Direct | 0 |
Reported balance
After 2020-01-16 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2020-01-16 · Disposition to issuer · Disposed 15,000 · Balance 0 F2: Pursuant to the Merger Agreement, immediately prior to the Effective Time, all outstanding Company stock options, to the extent unvested, became fully vested, and at the Effective Time, each outstanding Company stock option was cancelled and converted into the right to receive an amount of cash (subject to any applicable withholding or other taxes required by applicable law) determined by multiplying (i) the number of shares of Company common stock subject to such stock option immediately prior to such cancellation by (ii) the excess, if any, of an amount in cash equal to the Offer Price, without any interest, over the exercise price per share of Company common sotck subject to such stock option, less any applicable tax withholding. Any such option that had an exercise price that equaled or exceeded the Offer Price was cancelled for no consideration. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.71 · Expires 2021-06-01 | Direct | 0 |
Reported balance
After 2020-01-16 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2020-01-16 · Disposition to issuer · Disposed 15,000 · Balance 0 F2: Pursuant to the Merger Agreement, immediately prior to the Effective Time, all outstanding Company stock options, to the extent unvested, became fully vested, and at the Effective Time, each outstanding Company stock option was cancelled and converted into the right to receive an amount of cash (subject to any applicable withholding or other taxes required by applicable law) determined by multiplying (i) the number of shares of Company common stock subject to such stock option immediately prior to such cancellation by (ii) the excess, if any, of an amount in cash equal to the Offer Price, without any interest, over the exercise price per share of Company common sotck subject to such stock option, less any applicable tax withholding. Any such option that had an exercise price that equaled or exceeded the Offer Price was cancelled for no consideration. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.82 · Expires 2022-05-24 | Direct | 0 |
Reported balance
After 2020-01-16 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2020-01-16 · Disposition to issuer · Disposed 15,000 · Balance 0 F2: Pursuant to the Merger Agreement, immediately prior to the Effective Time, all outstanding Company stock options, to the extent unvested, became fully vested, and at the Effective Time, each outstanding Company stock option was cancelled and converted into the right to receive an amount of cash (subject to any applicable withholding or other taxes required by applicable law) determined by multiplying (i) the number of shares of Company common stock subject to such stock option immediately prior to such cancellation by (ii) the excess, if any, of an amount in cash equal to the Offer Price, without any interest, over the exercise price per share of Company common sotck subject to such stock option, less any applicable tax withholding. Any such option that had an exercise price that equaled or exceeded the Offer Price was cancelled for no consideration. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.78 · Expires 2023-05-20 | Direct | 0 |
Reported balance
After 2020-01-16 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2020-01-16 · Disposition to issuer · Disposed 15,000 · Balance 0 F2: Pursuant to the Merger Agreement, immediately prior to the Effective Time, all outstanding Company stock options, to the extent unvested, became fully vested, and at the Effective Time, each outstanding Company stock option was cancelled and converted into the right to receive an amount of cash (subject to any applicable withholding or other taxes required by applicable law) determined by multiplying (i) the number of shares of Company common stock subject to such stock option immediately prior to such cancellation by (ii) the excess, if any, of an amount in cash equal to the Offer Price, without any interest, over the exercise price per share of Company common sotck subject to such stock option, less any applicable tax withholding. Any such option that had an exercise price that equaled or exceeded the Offer Price was cancelled for no consideration. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.42 · Expires 2024-05-13 | Direct | 0 |
Reported balance
After 2020-01-16 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2020-01-16 · Disposition to issuer · Disposed 15,000 · Balance 0 F2: Pursuant to the Merger Agreement, immediately prior to the Effective Time, all outstanding Company stock options, to the extent unvested, became fully vested, and at the Effective Time, each outstanding Company stock option was cancelled and converted into the right to receive an amount of cash (subject to any applicable withholding or other taxes required by applicable law) determined by multiplying (i) the number of shares of Company common stock subject to such stock option immediately prior to such cancellation by (ii) the excess, if any, of an amount in cash equal to the Offer Price, without any interest, over the exercise price per share of Company common sotck subject to such stock option, less any applicable tax withholding. Any such option that had an exercise price that equaled or exceeded the Offer Price was cancelled for no consideration. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.80 · Expires 2025-05-11 | Direct | 0 |
Reported balance
After 2020-01-16 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2020-01-16 · Disposition to issuer · Disposed 15,000 · Balance 0 F2: Pursuant to the Merger Agreement, immediately prior to the Effective Time, all outstanding Company stock options, to the extent unvested, became fully vested, and at the Effective Time, each outstanding Company stock option was cancelled and converted into the right to receive an amount of cash (subject to any applicable withholding or other taxes required by applicable law) determined by multiplying (i) the number of shares of Company common stock subject to such stock option immediately prior to such cancellation by (ii) the excess, if any, of an amount in cash equal to the Offer Price, without any interest, over the exercise price per share of Company common sotck subject to such stock option, less any applicable tax withholding. Any such option that had an exercise price that equaled or exceeded the Offer Price was cancelled for no consideration. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.68 · Expires 2026-05-24 | Direct | 0 |
Reported balance
After 2020-01-16 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2020-01-16 · Disposition to issuer · Disposed 20,000 · Balance 0 F2: Pursuant to the Merger Agreement, immediately prior to the Effective Time, all outstanding Company stock options, to the extent unvested, became fully vested, and at the Effective Time, each outstanding Company stock option was cancelled and converted into the right to receive an amount of cash (subject to any applicable withholding or other taxes required by applicable law) determined by multiplying (i) the number of shares of Company common stock subject to such stock option immediately prior to such cancellation by (ii) the excess, if any, of an amount in cash equal to the Offer Price, without any interest, over the exercise price per share of Company common sotck subject to such stock option, less any applicable tax withholding. Any such option that had an exercise price that equaled or exceeded the Offer Price was cancelled for no consideration. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.23 · Expires 2027-05-23 | Direct | 0 |
Reported balance
After 2020-01-16 transaction · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · 2020-01-16 · Disposition to issuer · Disposed 20,000 · Balance 0 F2: Pursuant to the Merger Agreement, immediately prior to the Effective Time, all outstanding Company stock options, to the extent unvested, became fully vested, and at the Effective Time, each outstanding Company stock option was cancelled and converted into the right to receive an amount of cash (subject to any applicable withholding or other taxes required by applicable law) determined by multiplying (i) the number of shares of Company common stock subject to such stock option immediately prior to such cancellation by (ii) the excess, if any, of an amount in cash equal to the Offer Price, without any interest, over the exercise price per share of Company common sotck subject to such stock option, less any applicable tax withholding. Any such option that had an exercise price that equaled or exceeded the Offer Price was cancelled for no consideration. |
Filing footnotes · ownership attribution and instrument terms
F1: On December 6, 2019, ArQule, Inc. (the "Company") entered into an Agreement and Plan of Merger (as amended, supplemented or otherwise modified from time to time, the "Merger Agreement") with Merck Sharpe & Dohme Corp. ("MSD") and Argon Merger Sub, Inc., a wholly-owned subsidiary of MSD ("Merger Sub"), pursuant to which MSD acquired the Company by a tender offer for all shares of Company common stock (the "Offer") and a subsequent merger (the "Merger"), each of which became effective on January 16, 2020. Pursuant to the Merger Agreement, (i) Merger Sub purchased all shares of Company common stock that were validly tendered pursuant to the Offer for a cash payment equal to $20.00 per share (the "Offer Price") and (ii) all shares of Company common stock outstanding immediately prior to the effective time of the Merger (the "Effective Time"), were cancelled and converted automatically into the right to receive the Offer Price.
F2: Pursuant to the Merger Agreement, immediately prior to the Effective Time, all outstanding Company stock options, to the extent unvested, became fully vested, and at the Effective Time, each outstanding Company stock option was cancelled and converted into the right to receive an amount of cash (subject to any applicable withholding or other taxes required by applicable law) determined by multiplying (i) the number of shares of Company common stock subject to such stock option immediately prior to such cancellation by (ii) the excess, if any, of an amount in cash equal to the Offer Price, without any interest, over the exercise price per share of Company common sotck subject to such stock option, less any applicable tax withholding. Any such option that had an exercise price that equaled or exceeded the Offer Price was cancelled for no consideration.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 08, 2018 Filed Mar 9, 2018 21:09 UTC | VEEVA SYSTEMS INC VEEV · Entity 2124 | SaleClass A Common Stock | 1,993 | $78.16 | $155,772.88 |
DisclosureSEC source: 0001209191-18-018473 · doc4.xml · nonDerivative · entry 1 BARABE TIMOTHY C · CIK 0001237409 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,191 Read SEC document |
| December 21, 2017 Filed Dec 22, 2017 22:10 UTC | VEEVA SYSTEMS INC VEEV · Entity 2124 | Exercise / conversionRestricted Stock Units · Derivative | 701 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-067111 · doc4.xml · derivative · entry 2 BARABE TIMOTHY C · CIK 0001237409 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,402 Underlying: Class A Common Stock · 701 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Class A Common Stock of the Issuer. F1 · date: Transaction exempt from Section 16(b) of the Securities Exchange Act of 1934 (the "Act") pursuant to Rule 16b-6(b) promulgated under the Act. F3 · derivative.exercise_date: On June 21, 2017, the Reporting Person was granted 2,804 RSUs under the Issuer's 2013 Equity Incentive Plan, of which 1/4 of the RSUs vested on September 21, 2017, with the remaining RSUs vesting equally on a quarterly basis thereafter, subject to continued service on the Issuer's board of directors on the applicable vesting date. F3 · derivative.expiration_date: On June 21, 2017, the Reporting Person was granted 2,804 RSUs under the Issuer's 2013 Equity Incentive Plan, of which 1/4 of the RSUs vested on September 21, 2017, with the remaining RSUs vesting equally on a quarterly basis thereafter, subject to continued service on the Issuer's board of directors on the applicable vesting date. Read SEC document |
| December 21, 2017 Filed Dec 22, 2017 22:10 UTC | VEEVA SYSTEMS INC VEEV · Entity 2124 | Exercise / conversionClass A Common Stock | 701 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-067111 · doc4.xml · nonDerivative · entry 1 BARABE TIMOTHY C · CIK 0001237409 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,184 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · date: Transaction exempt from Section 16(b) of the Securities Exchange Act of 1934 (the "Act") pursuant to Rule 16b-6(b) promulgated under the Act. F2 · price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Class A Common Stock of the Issuer. Read SEC document |
| November 10, 2017 Filed Nov 13, 2017 23:18 UTC | Cartesian Therapeutics, Inc. SELB · Entity 6015 | PurchaseCommon Stock | 2,500 | $9.00 | $22,504.75 |
DisclosureSEC source: 0001638599-17-001128 · doc4_5063.xml · nonDerivative · entry 2 BARABE TIMOTHY C · CIK 0001237409 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,492 Read SEC document |
| November 09, 2017 Filed Nov 13, 2017 23:18 UTC | Cartesian Therapeutics, Inc. SELB · Entity 6015 | PurchaseCommon Stock | 2,500 | $9.73 | $24,335.25 |
DisclosureSEC source: 0001638599-17-001128 · doc4_5063.xml · nonDerivative · entry 1 BARABE TIMOTHY C · CIK 0001237409 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,992 Read SEC document |
| September 21, 2017 Filed Sep 25, 2017 20:46 UTC | VEEVA SYSTEMS INC VEEV · Entity 2124 | Exercise / conversionRestricted Stock Units · Derivative | 701 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-053831 · doc4.xml · derivative · entry 2 BARABE TIMOTHY C · CIK 0001237409 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,103 Underlying: Class A Common Stock · 701 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Class A Common Stock of the Issuer. F1 · date: Transaction exempt from Section 16(b) of the Securities Exchange Act of 1934 (the "Act") pursuant to Rule 16b-6(b) promulgated under the Act. F3 · derivative.exercise_date: On June 21, 2017, the Reporting Person was granted 2,804 RSUs under the Issuer's 2013 Equity Incentive Plan, of which 1/4 of the RSUs will vest on September 21, 2017, with the remaining RSUs vesting equally on a quarterly basis thereafter, subject to continued service on the Issuer's board of directors on the applicable vesting date. F3 · derivative.expiration_date: On June 21, 2017, the Reporting Person was granted 2,804 RSUs under the Issuer's 2013 Equity Incentive Plan, of which 1/4 of the RSUs will vest on September 21, 2017, with the remaining RSUs vesting equally on a quarterly basis thereafter, subject to continued service on the Issuer's board of directors on the applicable vesting date. Read SEC document |
| September 21, 2017 Filed Sep 25, 2017 20:46 UTC | VEEVA SYSTEMS INC VEEV · Entity 2124 | Exercise / conversionClass A Common Stock | 701 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-053831 · doc4.xml · nonDerivative · entry 1 BARABE TIMOTHY C · CIK 0001237409 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,483 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · date: Transaction exempt from Section 16(b) of the Securities Exchange Act of 1934 (the "Act") pursuant to Rule 16b-6(b) promulgated under the Act. F2 · price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Class A Common Stock of the Issuer. Read SEC document |
| June 22, 2017 Filed Jun 23, 2017 20:31 UTC | VEEVA SYSTEMS INC VEEV · Entity 2124 | Exercise / conversionRestricted Stock Units · Derivative | 1,292 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-041658 · doc4.xml · derivative · entry 3 BARABE TIMOTHY C · CIK 0001237409 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 1,292 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Class A Common Stock of the Issuer. F1 · date: Transaction exempt from Section 16(b) of the Securities Exchange Act of 1934 (the "Act") pursuant to Rule 16b-6(b) promulgated under the Act. F4 · derivative.exercise_date: On June 22, 2016, the Reporting Person was granted 5,168 RSUs under the Issuer's 2013 Equity Incentive Plan, of which 1/4 of the RSUs will vest on September 22, 2016, and the remaining RSUs vesting equally on a quarterly basis thereafter, subject to continued service on the Issuer's board of directors on the applicable vesting date. F4 · derivative.expiration_date: On June 22, 2016, the Reporting Person was granted 5,168 RSUs under the Issuer's 2013 Equity Incentive Plan, of which 1/4 of the RSUs will vest on September 22, 2016, and the remaining RSUs vesting equally on a quarterly basis thereafter, subject to continued service on the Issuer's board of directors on the applicable vesting date. Read SEC document |
| June 22, 2017 Filed Jun 23, 2017 20:31 UTC | VEEVA SYSTEMS INC VEEV · Entity 2124 | Exercise / conversionClass A Common Stock | 1,292 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-041658 · doc4.xml · nonDerivative · entry 1 BARABE TIMOTHY C · CIK 0001237409 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,782 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · date: Transaction exempt from Section 16(b) of the Securities Exchange Act of 1934 (the "Act") pursuant to Rule 16b-6(b) promulgated under the Act. F2 · price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Class A Common Stock of the Issuer. Read SEC document |
| June 21, 2017 Filed Jun 23, 2017 20:31 UTC | VEEVA SYSTEMS INC VEEV · Entity 2124 | GrantRestricted Stock Units · Derivative | 2,804 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-041658 · doc4.xml · derivative · entry 2 BARABE TIMOTHY C · CIK 0001237409 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,804 Underlying: Class A Common Stock · 2,804 shares Expires not disclosed F2 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Class A Common Stock of the Issuer. F3 · derivative.exercise_date: The RSUs were granted under the Issuer's 2013 Equity Incentive Plan. The Reporting Person vests ownership in the RSUs over one year, with 1/4 of the RSUs vesting on September 21, 2017, and the remaining RSUs vesting equally on a quarterly basis thereafter, subject to continued service by the Reporting Person to the Issuer. F3 · derivative.expiration_date: The RSUs were granted under the Issuer's 2013 Equity Incentive Plan. The Reporting Person vests ownership in the RSUs over one year, with 1/4 of the RSUs vesting on September 21, 2017, and the remaining RSUs vesting equally on a quarterly basis thereafter, subject to continued service by the Reporting Person to the Issuer. Read SEC document |
| June 16, 2017 Filed Jun 20, 2017 20:32 UTC | Cartesian Therapeutics, Inc. SELB · Entity 6015 | GrantStock Option (Right to Buy) · Derivative | 6,410 | $0.00 Strike: $17.47 | $0.00 |
DisclosureSEC source: 0001638599-17-000630 · doc4_4806.xml · derivative · entry 1 BARABE TIMOTHY C · CIK 0001237409 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,410 Underlying: Common Stock · 6,410 shares Expires 2027-06-15 F1 · derivative.exercise_date: The option vests in full on the earlier of June 16, 2018 or the day immediately prior to the company's 2018 annual meeting of shareholders. Read SEC document |
| May 23, 2017 Filed May 24, 2017 10:39 UTC | ARQULE INC ARQL · Entity 11927 | GrantDirector Stock Options · Derivative | 20,000 | $0.00 Strike: $1.23 | $0.00 |
DisclosureSEC source: 0001019695-17-000015 · primary_doc.xml · derivative · entry 1 BARABE TIMOTHY C · CIK 0001237409 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2027-05-23 F1 · derivative.exercise_date: The options vest one year from the date of grant May 23, 2017. Read SEC document |
| March 30, 2017 Filed Apr 3, 2017 20:02 UTC | VEEVA SYSTEMS INC VEEV · Entity 2124 | SaleClass A Common Stock | 1,292 | $51.04 | $65,943.68 |
DisclosureSEC source: 0001209191-17-024112 · doc4.xml · nonDerivative · entry 1 BARABE TIMOTHY C · CIK 0001237409 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,490 Read SEC document |
| March 27, 2017 Filed Apr 4, 2017 20:02 UTC | Cartesian Therapeutics, Inc. SELB · Entity 6015 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,492 | $0.00 Strike: $11.00 | $0.00 |
DisclosureSEC source: 0001104659-17-021351 · a4.xml · derivative · entry 2 BARABE TIMOTHY C · CIK 0001237409 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,328 Underlying: Common Stock · 2,492 shares Expires 2026-07-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The option vests in thirty-six (36) substantially equal monthly installments over three years following the date of grant. Read SEC document |
| March 27, 2017 Filed Apr 4, 2017 20:02 UTC | Cartesian Therapeutics, Inc. SELB · Entity 6015 | Exercise / conversionCommon Stock | 2,492 | $11.00 | $27,412.00 |
DisclosureSEC source: 0001104659-17-021351 · a4.xml · nonDerivative · entry 1 BARABE TIMOTHY C · CIK 0001237409 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,492 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 22, 2017 Filed Mar 24, 2017 20:56 UTC | VEEVA SYSTEMS INC VEEV · Entity 2124 | Exercise / conversionRestricted Stock Units · Derivative | 1,292 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-022779 · doc4.xml · derivative · entry 2 BARABE TIMOTHY C · CIK 0001237409 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,292 Underlying: Class A Common Stock · 1,292 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Class A Common Stock of the Issuer. F1 · date: Transaction exempt from Section 16(b) of the Securities Exchange Act of 1934 (the "Act") pursuant to Rule 16b-6(b) promulgated under the Act. F3 · derivative.exercise_date: On June 22, 2016, the Reporting Person was granted 5,168 RSUs under the Issuer's 2013 Equity Incentive Plan, of which 1/4 of the RSUs will vest on September 22, 2016, and the remaining RSUs vesting equally on a quarterly basis thereafter, subject to continued service on the Issuer's board of directors on the applicable vesting date. F3 · derivative.expiration_date: On June 22, 2016, the Reporting Person was granted 5,168 RSUs under the Issuer's 2013 Equity Incentive Plan, of which 1/4 of the RSUs will vest on September 22, 2016, and the remaining RSUs vesting equally on a quarterly basis thereafter, subject to continued service on the Issuer's board of directors on the applicable vesting date. Read SEC document |
| March 22, 2017 Filed Mar 24, 2017 20:56 UTC | VEEVA SYSTEMS INC VEEV · Entity 2124 | Exercise / conversionClass A Common Stock | 1,292 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-022779 · doc4.xml · nonDerivative · entry 1 BARABE TIMOTHY C · CIK 0001237409 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,782 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · date: Transaction exempt from Section 16(b) of the Securities Exchange Act of 1934 (the "Act") pursuant to Rule 16b-6(b) promulgated under the Act. F2 · price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Class A Common Stock of the Issuer. Read SEC document |
| February 18, 2017 Filed Feb 21, 2017 09:39 UTC | ARQULE INC ARQL · Entity 11927 | GrantCommon Stock | 5,000 | $1.20 | $6,000.00 |
DisclosureSEC source: 0001019695-17-000008 · primary_doc.xml · nonDerivative · entry 1 BARABE TIMOTHY C · CIK 0001237409 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 136,897 Read SEC document |
| January 17, 2017 Filed Jan 18, 2017 15:30 UTC | ARQULE INC ARQL · Entity 11927 | GrantCommon Stock | 784 | $1.53 | $1,199.52 |
DisclosureSEC source: 0001019695-17-000002 · primary_doc.xml · nonDerivative · entry 1 BARABE TIMOTHY C · CIK 0001237409 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 131,897 Read SEC document |
| December 30, 2016 Filed Jan 4, 2017 21:17 UTC | VEEVA SYSTEMS INC VEEV · Entity 2124 | SaleClass A Common Stock | 1,292 | $40.54 | $52,379.62 |
DisclosureSEC source: 0001209191-17-000859 · doc4.xml · nonDerivative · entry 1 BARABE TIMOTHY C · CIK 0001237409 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,490 Read SEC document |
| December 22, 2016 Filed Dec 28, 2016 00:07 UTC | VEEVA SYSTEMS INC VEEV · Entity 2124 | Exercise / conversionRestricted Stock Units · Derivative | 1,292 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-16-156851 · doc4.xml · derivative · entry 2 BARABE TIMOTHY C · CIK 0001237409 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,584 Underlying: Class A Common Stock · 1,292 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Class A Common Stock of the Issuer. F1 · date: Transaction exempt from Section 16(b) of the Securities Exchange Act of 1934 (the "Act") pursuant to Rule 16b-6(b) promulgated under the Act. F3 · derivative.exercise_date: On June 22, 2016, the Reporting Person was granted 5,168 RSUs under the Issuer's 2013 Equity Incentive Plan, of which 1/4 of the RSUs will vest on September 22, 2016, and the remaining RSUs vesting equally on a quarterly basis thereafter, subject to continued service on the Issuer's board of directors on the applicable vesting date. F3 · derivative.expiration_date: On June 22, 2016, the Reporting Person was granted 5,168 RSUs under the Issuer's 2013 Equity Incentive Plan, of which 1/4 of the RSUs will vest on September 22, 2016, and the remaining RSUs vesting equally on a quarterly basis thereafter, subject to continued service on the Issuer's board of directors on the applicable vesting date. Read SEC document |
| December 22, 2016 Filed Dec 28, 2016 00:07 UTC | VEEVA SYSTEMS INC VEEV · Entity 2124 | Exercise / conversionClass A Common Stock | 1,292 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-16-156851 · doc4.xml · nonDerivative · entry 1 BARABE TIMOTHY C · CIK 0001237409 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,782 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · date: Transaction exempt from Section 16(b) of the Securities Exchange Act of 1934 (the "Act") pursuant to Rule 16b-6(b) promulgated under the Act. F2 · price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Class A Common Stock of the Issuer. Read SEC document |
| November 18, 2016 Filed Nov 21, 2016 10:39 UTC | ARQULE INC ARQL · Entity 11927 | GrantCommon Stock | 4,285 | $1.40 | $5,999.00 |
DisclosureSEC source: 0001019695-16-000099 · primary_doc.xml · nonDerivative · entry 1 BARABE TIMOTHY C · CIK 0001237409 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 131,113 Read SEC document |
| November 18, 2016 Filed Nov 22, 2016 07:31 UTC | Acer Therapeutics Inc. OPXA · Entity 108116 | SaleWarrants (Right to Buy) · Derivative | 16,000 | $0.01 Strike: $12.00 | $94.40 |
DisclosureSEC source: 0001354488-16-008580 · issuerdirect_section16.xml · derivative · entry 3 BARABE TIMOTHY C · CIK 0001237409 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 16,000 shares Expires 2018-04-08 Read SEC document |
| November 18, 2016 Filed Nov 22, 2016 07:31 UTC | Acer Therapeutics Inc. OPXA · Entity 108116 | SaleCommon Stock | 7,809 | $0.55 | $4,301.98 |
DisclosureSEC source: 0001354488-16-008580 · issuerdirect_section16.xml · nonDerivative · entry 2 BARABE TIMOTHY C · CIK 0001237409 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,910 Read SEC document |
| November 18, 2016 Filed Nov 22, 2016 07:31 UTC | Acer Therapeutics Inc. OPXA · Entity 108116 | SaleCommon Stock | 7,105 | $0.55 | $3,907.75 |
DisclosureSEC source: 0001354488-16-008580 · issuerdirect_section16.xml · nonDerivative · entry 1 BARABE TIMOTHY C · CIK 0001237409 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,719 Read SEC document |
| November 15, 2016 Filed Nov 16, 2016 10:54 UTC | ARQULE INC ARQL · Entity 11927 | GrantCommon Stock | 1,413 | $1.38 | $1,949.94 |
DisclosureSEC source: 0001019695-16-000097 · primary_doc.xml · nonDerivative · entry 1 BARABE TIMOTHY C · CIK 0001237409 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 126,828 Read SEC document |
| October 25, 2016 Filed Oct 26, 2016 13:05 UTC | ARQULE INC ARQL · Entity 11927 | GrantCommon Stock | 531 | $1.41 | $748.71 |
DisclosureSEC source: 0001019695-16-000094 · primary_doc.xml · nonDerivative · entry 1 BARABE TIMOTHY C · CIK 0001237409 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,415 Read SEC document |
| September 30, 2016 Filed Oct 4, 2016 08:00 UTC | Acer Therapeutics Inc. OPXA · Entity 108116 | GrantCommon Stock | 6,455 | $0.00 | $0.00 |
DisclosureSEC source: 0001354488-16-008337 · issuerdirect_section16.xml · nonDerivative · entry 1 BARABE TIMOTHY C · CIK 0001237409 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,824 Read SEC document |
| September 22, 2016 Filed Sep 26, 2016 20:44 UTC | VEEVA SYSTEMS INC VEEV · Entity 2124 | Exercise / conversionRestricted Stock Units · Derivative | 1,292 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-16-142808 · doc4.xml · derivative · entry 2 BARABE TIMOTHY C · CIK 0001237409 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,876 Underlying: Class A Common Stock · 1,292 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Class A Common Stock of the Issuer. F1 · date: Transaction exempt from Section 16(b) of the Securities Exchange Act of 1934 (the "Act") pursuant to Rule 16b-6(b) promulgated under the Act. F3 · derivative.exercise_date: On June 22, 2016, the Reporting Person was granted 5,168 RSUs under the Issuer's 2013 Equity Incentive Plan, of which 1/4 of the RSUs will vest on September 22, 2016, and the remaining RSUs vesting equally on a quarterly basis thereafter, subject to continued service on the Issuer's board of directors on the applicable vesting date. F3 · derivative.expiration_date: On June 22, 2016, the Reporting Person was granted 5,168 RSUs under the Issuer's 2013 Equity Incentive Plan, of which 1/4 of the RSUs will vest on September 22, 2016, and the remaining RSUs vesting equally on a quarterly basis thereafter, subject to continued service on the Issuer's board of directors on the applicable vesting date. Read SEC document |
| September 22, 2016 Filed Sep 26, 2016 20:44 UTC | VEEVA SYSTEMS INC VEEV · Entity 2124 | Exercise / conversionClass A Common Stock | 1,292 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-16-142808 · doc4.xml · nonDerivative · entry 1 BARABE TIMOTHY C · CIK 0001237409 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,490 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · date: Transaction exempt from Section 16(b) of the Securities Exchange Act of 1934 (the "Act") pursuant to Rule 16b-6(b) promulgated under the Act. F2 · price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Class A Common Stock of the Issuer. Read SEC document |
| September 20, 2016 Filed Sep 22, 2016 11:23 UTC | ARQULE INC ARQL · Entity 11927 | GrantCommon Stock | 1,500 | $1.60 | $2,400.00 |
DisclosureSEC source: 0001019695-16-000092 · primary_doc.xml · nonDerivative · entry 1 BARABE TIMOTHY C · CIK 0001237409 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 124,884 Read SEC document |
| July 29, 2016 Filed Apr 4, 2017 20:01 UTC Amendment | Cartesian Therapeutics, Inc. SELB · Entity 6015 | GrantStock Option (Right to Buy) · Derivative | 12,820 | $0.00 Strike: $11.00 | $0.00 |
DisclosureSEC source: 0001104659-17-021348 · a4a.xml · derivative · entry 1 BARABE TIMOTHY C · CIK 0001237409 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,820 Underlying: Common Stock · 12,820 shares Expires 2026-07-28 F1 · derivative.exercise_price: The Form 4 filed on August 2, 2016 contained a Scrivener's error in the exercise price. This amendment has been filed solely to correct the exercise price of the July 29, 2016 grant from $10.99 to $11.00 per share. F2 · derivative.exercise_date: The option vests in thirty-six (36) substantially equal monthly installments over three years following the date of grant. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.